NICE guidance on obesity and weight management recognises that sustained weight loss of 10% or more can significantly reduce the risk of type 2 diabetes, cardiovascular disease, and musculoskeletal problems
Semaglutide and tirzepatide shortages have largely resolved in 2025, but demand remains high
In studies, semaglutide was more effective at reducing body weight and HbA1c than placebo
Wie uitsluitend vertrouwt op medicatie zonder aan onderliggende patronen te werken, zal merken dat de kilos snel terugkomen zodra de behandeling stopt
Avoid fried or fatty foods and dishes heavy on cheese, which can increase bloating, diarrhea and other GI symptoms
Authoritative review describing how GLP-1 and clinically approved GLP-1R agonists engage mechanisms that influence the risk of developing cardiovascular disease in diabetes and obesity